AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jun 26, 2014

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer

NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. Specifically, the combination of veliparib, carboplatin and paclitaxel will be compared to treatment with carboplatin, paclitaxel and placebo in patients with human epidermal growth factor receptor 2-(HER2) negative metastatic or locally-advanced breast cancer, containing BRCA1 and/or BRCA2 gene mutations.

Jun 23, 2014

AbbVie Raises Outlook for 2014

NORTH CHICAGO, Ill., June 23, 2014 – AbbVie (NYSE: ABBV) today raised the midpoint of  its full-year 2014 earnings-per-share guidance by six cents and now expects a full-year diluted earnings-per-share range of $3.06 to $3.16 on an adjusted basis, or $2.69 to $2.79 on a GAAP basis. AbbVie's 2014 outlook continues to exclude any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy which has been granted accelerated review by the U.S. Food and Drug Administration (FDA).

Jun 20, 2014

Response to Press Speculation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Jun 19, 2014

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 19, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share. 

Jun 17, 2014

European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA).

Jun 16, 2014

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis

CAMBRIDGE, Mass. and NORTH CHICAGO, Ill. – June 16, 2014 – Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE:ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular  interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). 

Jun 13, 2014

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.

Jun 11, 2014

AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases

PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.

Jun 10, 2014

AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., June 10, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.